Global Iohexol API Market Growth 2025-2031
The global Iohexol API market size is predicted to grow from US$ 616 million in 2025 to US$ 933 million in 2031; it is expected to grow at a CAGR of 7.2% from 2025 to 2031.
Iohexol was first listed in Norway and Sweden in 1982. It is a kind of second-generation non-ionic monomeric contrast agent. Iopromide, Iomeprol, etc. Iohexol has low osmotic pressure, low toxicity to the nervous system, low contrast density, and good tolerance. It can be used for angiography, subarachnoid angiography, coronary angiography, spinal cord and femoral joints, urology angiography, and enhanced CT scanning. Etc., is the "gold standard" for evaluating various X-ray contrast agents in the medical community.
Global key manufacturers of Iohexol API include GE Healthcare, Otsuka Chemicals, Starry, etc. Global top three manufacturers hold a share about 85%. Europe is the largest market of Iohexol API, holds a share over 60%. In terms of product, the Original Drug holds a larger segment, with a share over 80%. And in terms of application, the largest application is Hospitals, with a share of over 90%.
LP Information, Inc. (LPI) ' newest research report, the “Iohexol API Industry Forecast” looks at past sales and reviews total world Iohexol API sales in 2024, providing a comprehensive analysis by region and market sector of projected Iohexol API sales for 2025 through 2031. With Iohexol API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Iohexol API industry.
This Insight Report provides a comprehensive analysis of the global Iohexol API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Iohexol API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Iohexol API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Iohexol API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Iohexol API.
This report presents a comprehensive overview, market shares, and growth opportunities of Iohexol API market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Original Drug
Generic Drug
Segmentation by Application:
Hospitals
Clinics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
GE Healthcare
Otsuka Chemicals
Justesa Imagen
Starry Pharmaceutical
Haichang Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Iohexol API market?
What factors are driving Iohexol API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Iohexol API market opportunities vary by end market size?
How does Iohexol API break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.